Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations

American Journal of Drug and Alcohol Abuse

Volumn 45, Issue 6, 2019, Pages 644-663

  Smart, Rosanna ^a   Pacula, Rosalie Liccardo ^a,b  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

alcohol; Cannabis; drug policy; opioids; substitution; tobacco

Indexed keywords

MEDICAL CANNABIS;

ALCOHOL CONSUMPTION; CANNABIS ADDICTION; CANNABIS USE; EVALUATION STUDY; EVIDENCE BASED PRACTICE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; LAW; LEGAL ASPECT; OPIATE ADDICTION; QUASI EXPERIMENTAL STUDY; REVIEW; SUBSTANCE USE; SYSTEMATIC REVIEW; TOBACCO USE; ADOLESCENT; ADULT; AGE; DRINKING BEHAVIOR; DRUG DEPENDENCE; DRUG LEGISLATION; LEGISLATION AND JURISPRUDENCE; PUBLIC POLICY;

ADOLESCENT; ADULT; AGE FACTORS; ALCOHOL DRINKING; HUMANS; LEGISLATION, DRUG; MARIJUANA ABUSE; MARIJUANA USE; MEDICAL MARIJUANA; OPIOID-RELATED DISORDERS; PUBLIC POLICY; SUBSTANCE-RELATED DISORDERS; TOBACCO USE;

EID: 85074336108     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990.2019.1669626     Document Type: Review

References (118)

1. National Conference of State Legislatures. Marijuana deep dive. Washington, DC: National Conference of State Legislatures; 2018. Retrieved from: http://www.ncsl.org/bookstore/state-legislatures-magazine/marijuana-deep-dive.aspx.
2. Hartig H, Geiger A., About six-in-ten Americans support marijuana legalization. Washington, DC: Pew Research Center; 2018. Retrieved from: http://www.pewresearch.org/fact-tank/2018/10/08/americans-support-marijuana-legalization/.
3. National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.
4. Jones JM., In U.S., medical aid top reason why legal marijuana favored. Gallup; 2019. Retrieved from: https://news.gallup.com/poll/258149/medical-aid-top-reason-why-legal-marijuana-favored.aspx [last accessed 12 June 2019].
5. Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA., CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005–2013; 2014.
6. Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD., 2010 national and state costs of excessive alcohol consumption. Am J Prev Med. 2015;49:e73–e9. doi:10.1016/j.amepre.2015.05.031.
7. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. The Lancet. 2014;384:45–52. doi:10.1016/S0140-6736(14)60648-6.
8. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54:901–06. doi:10.1097/MLR.0000000000000625.
9. Pacula RL, Grossman M, Chaloupka FJ, O’Malley PM, Johnston L, Farrelly MC. Marijuana and youth. In: Gruber J, editor. Risky behavior among youths: an economic analysis. Chicago, IL: University of Chicago Press; 2001. p. 271–326.
10. Pacula RL, Kilmer B, Grossman M, Chaloupka FJ. Risks and prices: the role of user sanctions in marijuana markets. B E J Econom Anal Policy. 2010;10. Article 11. doi:10.2202/1935-1682.1992.
11. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201. doi:10.1016/j.drugpo.2008.10.003.
12. Pacula RL, Smart R. Medical marijuana and marijuana legalization. Annu Rev Clin Psychol. 2017;13:397–419. doi:10.1146/annurev-clinpsy-032816-045128.
13. Pacula RL, Sevigny EL. Marijuana liberalization policies: why we can’t learn much from policy still in motion. J Pol Anal Manage. 2014;33:212–21. doi:10.1002/pam.21726.
14. Anderson DM, Rees DI. The role of dispensaries: the devil is in the details. J Pol Anal Manage. 2014;33:235–40. doi:10.1002/pam.21733.
15. Williams AR, Olfson M, Kim JH, Martins SS, Kleber HD, Older L. Regulated medical marijuana programs have much greater enrollment rates than newer `medicalized’ programs. Health Aff (Millwood). 2016;35:480–88. doi:10.1377/hlthaff.2015.0528.
16. Pacula RL, Boustead AE, Hunt P. Words can be deceiving: a review of variation among legally effective medical marijuana laws in the United States. J Drug Policy Anal. 2014;7:1–19. doi:10.1515/jdpa-2014-0001.
17. Leung J, Chiu CYV, Stjepanović D, Hall W. Has the legalisation of medical and recreational cannabis use in the USA affected the prevalence of cannabis use and cannabis use disorders?. Curr Addict Rep. 2018;5:403–17.
18. Chadi N, Weitzman ER, Levy S. Understanding the impact of national and state medical marijuana policies on adolescents. Curr Addict Rep. 2018;5:93–101.
19. Sarvet AL, Wall MM, Fink DS, Greene E, Le A, Boustead AE, Pacula RL, Keyes KM, Cerdá M, Galea S, et al. Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta‐analysis. Addiction. 2018;113:1003–16. doi:10.1111/add.14136.
20. Kilmer B, MacCoun RJ. How medical marijuana smoothed the transition to marijuana legalization in the United States. Annu Rev Law Social Sci. 2017;13:181–202. doi:10.1146/annurev-lawsocsci-110615-084851.
21. Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the US: a review. Prev Med. 2017;104:13–23. doi:10.1016/j.ypmed.2017.07.008.
22. Sznitman SR, Zolotov Y. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int J Drug Policy. 2015;26:20–29. doi:10.1016/j.drugpo.2014.09.005.
23. Choo EK, Emery SL. Clearing the haze: the complexities and challenges of research on state marijuana laws. Ann N Y Acad Sci. 2016;1394:55–73. doi:10.1111/nyas.13093.
24. Melchior M, Nakamura A, Bolze C, Hausfater F, El Khoury F, Mary-Krause M, Da Silva MA. Does liberalisation of cannabis policy influence levels of use in adolescents and young adults? A systematic review and meta-analysis. BMJ Open. 2019;9:e025880. doi:10.1136/bmjopen-2018-025880.
25. Keyes KM, Wall M, Cerdá M, Schulenberg J, O’Malley PM, Galea S, Feng T, Hasin DS. How does state marijuana policy affect US youth? Medical marijuana laws, marijuana use and perceived harmfulness: 1991-2014. Addiction. 2016;111:2187–95. doi:10.1111/add.13523.
26. Cerdá M, Sarvet AL, Wall M, Feng T, Keyes KM, Galea S, Hasin DS. Medical marijuana laws and adolescent use of marijuana and other substances: alcohol, cigarettes, prescription drugs, and other illicit drugs. Drug Alcohol Depend. 2018;183:62–68. doi:10.1016/j.drugalcdep.2017.10.021.
27. Lynne-Landsman SD, Livingston MD, Wagenaar AC. Effects of state medical marijuana laws on adolescent marijuana use. Am J Public Health. 2013;103:1500–06. doi:10.2105/AJPH.2012.301117.
28. Wall MM, Mauro C, Hasin DS, Keyes KM, Cerdá M, Martins SS, Feng T. Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: commentary on and reanalysis of US national survey on drug use in households data 2002-2011. Int J Drug Policy. 2016;29:9–13. doi:10.1016/j.drugpo.2016.01.015.
29. Choo EK, Benz M, Zaller N, Warren O, Rising KL, McConnell KJ. The impact of state medical marijuana legislation on adolescent marijuana use. J Adolesc Health. 2014;55:160–66. doi:10.1016/j.jadohealth.2014.02.018.
30. Johnson JK, Johnson RM, Hodgkin D, Jones AA, Matteucci AM, Harris SK. Heterogeneity of state medical marijuana laws and adolescent recent use of alcohol and marijuana: analysis of 45 states, 1991-2011. Subst Abus. 2018;39:247–54. doi:10.1080/08897077.2017.1389801.
31. Johnson J, Hodgkin D, Harris SK. The design of medical marijuana laws and adolescent use and heavy use of marijuana: analysis of 45 states from 1991 to 2011. Drug Alcohol Depend. 2017;170:1–8. doi:10.1016/j.drugalcdep.2016.10.028.
32. Anderson DM, Hansen B, Rees DI. Medical marijuana laws and teen marijuana use. Amer Law Econ Rev. 2015;17:495–528. doi:10.1093/aler/ahv002.
33. Harper S, Strumpf EC, Kaufman JS. Do medical marijuana laws increase marijuana use? Replication study and extension. Ann Epidemiol. 2012;22:207–12. doi:10.1016/j.annepidem.2011.12.002.
34. Martins SS, Mauro CM, Santaella-Tenorio J, Kim JH, Cerdá M, Keyes KM, Hasin DS, Galea S, Wall M. State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. Drug Alcohol Depend. 2016;169:26–32. doi:10.1016/j.drugalcdep.2016.10.004.
35. Williams AR, Santaella‐Tenorio J, Mauro CM, Levin FR, Martins SS. Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder. Addiction. 2017;112:1985–91. doi:10.1111/add.13904.
36. Wall MM, Poh E, Cerdá M, Keyes KM, Galea S, Hasin DS. Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear. Ann Epidemiol. 2011;21:714–16. doi:10.1016/j.annepidem.2011.06.001.
37. Coley RL, Hawkins SS, Ghiani M, Kruzik C, Baum CF. A quasi-experimental evaluation of marijuana policies and youth marijuana use. Am J Drug Alcohol Abuse. 2019;45:292–303. doi:10.1080/00952990.2018.1559847.
38. Hasin DS, Wall M, Keyes KM, Cerdá M, Schulenberg J, O’Malley PM, Galea S, Pacula R, Feng T. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry. 2015;2:601–08. doi:10.1016/S2215-0366(15)00217-5.
39. Mauro CM, Newswanger P, Santaella-Tenorio J, Mauro PM, Carliner H, Martins SS. Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004-2013. Prev Sci. 2019;20:205–14. doi:10.1007/s11121-017-0848-3.
40. Stolzenberg L, D’Alessio SJ, Dariano D. The effect of medical cannabis laws on juvenile cannabis use. Int J Drug Policy. 2016;27:82–88. doi:10.1016/j.drugpo.2015.05.018.
41. Wen H, Hockenberry JM, Cummings JR. The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J Health Econ. 2015;42:64–80. doi:10.1016/j.jhealeco.2015.03.007.
42. Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J Pol Anal Manage. 2015;34:7–31. doi:10.1002/pam.2015.34.issue-1.
43. Hasin DS, Sarvet AL, Cerdá M, Keyes KM, Stohl M, Galea S, Wall MM. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017;74:579–88. doi:10.1001/jamapsychiatry.2017.0724.
44. Choi A, Dave D, Sabia JJ. Smoke gets in your eyes: medical marijuana laws and tobacco cigarette use. Am J Health Econ. 2018;5:303–33.
45. Kerr WC, Lui C, Ye Y. Trends and age, period and cohort effects for marijuana use prevalence in the 1984-2015 US national alcohol surveys. Addiction. 2018;113:473–81. doi:10.1111/add.14031.
46. Smart R., Essays on the effects of medical marijuana laws [PhD Dissertation]. Los Angeles: University of California, Los Angeles; 2016.
47. Chapman SA, Spetz J, Lin J, Chan K, Schmidt LA. Capturing heterogeneity in medical marijuana policies: a taxonomy of regulatory regimes across the United States. Subst Use Misuse. 2016;51:1174–84. doi:10.3109/10826084.2016.1160932.
48. Hunt P, Miles JNV, Boustead A. Understanding patterns in medical marijuana laws: a latent class and transition analysis. Santa Monica, CA: RAND Health and RAND Justice, Infrastructure and Environment, RAND Corporation; 2013.
49. King EM, Behrman JR. Timing and duration of exposure in evaluations of social programs. World Bank Res Obs. 2009;24:55–82. doi:10.1093/wbro/lkn009.
50. Smart RG., Essays on the effects of medical marijuana laws [Doctoral Dissertation]. Los Angeles: University of California; 2016.
51. Cerdá M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, O’malley PM, Pacula RL, Galea S, Hasin DS. Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr. 2017;171:142–49.
52. Kerr DCR, Bae H, Koval AL. Oregon recreational marijuana legalization: changes in undergraduates’ marijuana use rates from 2008 to 2016. Psychol Addict Behav. 2018;32:670–78. doi:10.1037/adb0000385.
53. Kerr DC, Bae H, Phibbs S, Kern AC. Changes in undergraduates’ marijuana, heavy alcohol and cigarette use following legalization of recreational marijuana use in Oregon. Addiction. 2017;112:1992–2001. doi:10.1111/add.13906.
54. Miller AM, Rosenman R, Cowan BW. Recreational marijuana legalization and college student use: early evidence. SSM - Popul Health. 2017;3:649–57. doi:10.1016/j.ssmph.2017.08.001.
55. Hunt P, Pacula RL. Early impacts of marijuana legalization: an evaluation of prices in Colorado and Washington. J Prim Prev. 2017;38:221–48. doi:10.1007/s10935-017-0471-x.
56. Smart R, Caulkins JP, Kilmer B, Davenport SS, Midgette G. Variation in cannabis potency and prices in a newly-legal market: evidence from 30 million cannabis sales in Washington State. Addiction. 2017;112:2167–77. doi:10.1111/add.13886.
57. Chu Y-WL. The effects of medical marijuana laws on illegal marijuana use. J Health Econ. 2014;38:43–61. doi:10.1016/j.jhealeco.2014.07.003.
58. Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144–50. doi:10.1016/j.drugalcdep.2017.01.006.
59. Borodovsky JT, Crosier BS, Lee DC, Sargent JD, Budney AJ. Smoking, vaping, eating: is legalization impacting the way people use cannabis? Int J Drug Policy. 2016;36:141–47. doi:10.1016/j.drugpo.2016.02.022.
60. Borodovsky JT, Lee DC, Crosier BS, Gabrielli JL, Sargent JD, Budney AJ. US cannabis legalization and use of vaping and edible products among youth. Drug Alcohol Depend. 2017;177:299–306. doi:10.1016/j.drugalcdep.2017.02.017.
61. Daniulaityte R, Lamy FR, Barratt M, Nahhas RW, Martins SS, Boyer EW, Sheth A, Carlson RG. Characterizing marijuana concentrate users: a web-based survey. Drug Alcohol Depend. 2017;178:399–407. doi:10.1016/j.drugalcdep.2017.05.034.
62. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J. 2007;4:11. doi:10.1186/1477-7517-4-11.
63. Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of administration for cannabis use–basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018;52:87–96. doi:10.1016/j.drugpo.2017.11.008.
64. Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug Alcohol Depend. 2017;175:67–76. doi:10.1016/j.drugalcdep.2017.02.003.
65. Raber JC, Elzinga S, Kaplan C. Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci. 2015;40:797–803. doi:10.2131/jts.40.797.
66. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31:2296–303. doi:10.1038/sj.npp.1301068.
67. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013;59:478–92. doi:10.1373/clinchem.2012.194381.
68. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73:292–97. doi:10.1001/jamapsychiatry.2015.3278.
69. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav. 2014;39:1430–33. doi:10.1016/j.addbeh.2014.05.013.
70. D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558. doi:10.1038/sj.npp.1300496.
71. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488–91.
72. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. Int J Drug Policy. 2014;25:308–19. doi:10.1016/j.drugpo.2014.01.003.
73. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491–93. doi:10.1001/jama.2015.6613.
74. Carlini BH, Garrett SB, Harwick RM. Beyond joints and brownies: marijuana concentrates in the legal landscape of WA State. Int J Drug Policy. 2017;42:26–29. doi:10.1016/j.drugpo.2017.01.004.
75. Caulkins JP, Kilmer B, Kleiman MAR, MacCoun RJ, Midgette G, Oglesby P, Pacula RL, Reuter PH. Considering marijuana legalization: insights for vermont and other jurisdictions. Rand, editor. Santa Monica, CA: Rand Corporation; 2015.
76. Kilmer B, Caulkins JP, Pacula RL, MacCoun RJ, Reuter P. Altered state? Assessing how marijuana legalization in California could influence marijuana consumption and public budgets. Santa Monica, CA: The RAND Corporation; 2010.
77. Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees. JAMA Intern Med. 2018;178:673–79. doi:10.1001/jamainternmed.2018.1007.
78. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174:1668–73. doi:10.1001/jamainternmed.2014.4005.
79. Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018;58:29–42. doi:10.1016/j.jhealeco.2017.12.007.
80. Kleiman MA. Legal commercial cannabis sales in Colorado and Washington: what can we learn?. J Drug Policy Anal. 2016;10:1–16. doi:10.1515/jdpa-2015-0020
81. Hansen B, Miller K, Weber C. The taxation of recreational marijuana: evidence from Washington state. Cambridge, MA: National Bureau of Economic Research; 2017. Contract No.: 23632.
82. Anderson DM, Hansen B, Rees DI. Medical marijuana laws, traffic fatalities, and alcohol consumption. J Law Econ. 2013;56:333–69. doi:10.1086/668812.
83. Sabia JJ, Swigert J, Young T. The effect of medical marijuana laws on body weight. Health Econ. 2017;26:6–34. doi:10.1002/hec.3267.
84. Xuan Z, Blanchette J, Nelson TF, Heeren T, Oussayef N, Naimi TS. The alcohol policy environment and policy subgroups as predictors of binge drinking measures among US adults. Am J Public Health. 2015;105:816–22. doi:10.2105/AJPH.2014.302112.
85. Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, Lintzeris N, Khor KE, Farrell M, Smith A, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42:1752.
86. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456–73. doi:10.1001/jama.2015.6358.
87. Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, Degenhardt L. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159:1932–54. doi:10.1097/j.pain.0000000000001293.
88. Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009;6:1. doi:10.1186/1477-7517-6-35.
89. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–35. doi:10.1016/j.drugpo.2017.01.011.
90. Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2:160–66. doi:10.1089/can.2017.0012.
91. Caputi TL, Humphreys K. Medical marijuana users are more likely to use prescription drugs medically and nonmedically. J Addict Med. 2018;12:295–99. doi:10.1097/ADM.0000000000000405.
92. Phillips E, Gazmararian J. Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality. J Opioid Manag. 2017;13:229–39. doi:10.5055/jom.2017.0391.
93. Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. P Natl Acad Sci USA. 2019;116:12624–26. doi:10.1073/pnas.1903434116.
94. Chu Y-WL. Do medical marijuana laws increase hard-drug use? J Law Econ. 2015;58:481–517. doi:10.1086/684043.
95. Kim JH, Santaella-Tenorio J, Mauro C, Wrobel J, Cerdá M, Keyes KM, Hasin D, Martins SS, Li G. State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. Am J Public Health. 2016;106:2032–37. doi:10.2105/AJPH.2016.303426.
96. Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff. 2016;35:1230–36. doi:10.1377/hlthaff.2015.1661.
97. Shah A, Hayes CJ, Lakkad M, Martin BC. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J Gen Intern Med. 2019;34:1419–26. doi:10.1007/s11606-018-4782-2.
98. Wen H, Hockenberry JM, Druss BG. The effect of medical marijuana laws on marijuana-related attitude and perception among us adolescents and young adults. Prev Sci. 2019;20:215–23. doi:10.1007/s11121-018-0903-8.
99. Shi Y, Liang D, Bao Y, An R, Wallace MS, Grant I. Recreational marijuana legalization and prescription opioids received by medicaid enrollees. Drug Alcohol Depend. 2019;194:13–19. doi:10.1016/j.drugalcdep.2018.09.016.
100. Liang D, Bao Y, Wallace M, Grant I, Shi Y. Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction. 2018;113:2060–70. doi:10.1111/add.14382.
101. Bradford AC, Bradford WD. Factors driving the diffusion of medical marijuana legalisation in the United States. Drugs. 2017;24:75–84.
102. Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US State medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern Med. 2018;178:667–72. doi:10.1001/jamainternmed.2018.0266.
103. Doctor JN, Nguyen A, Lev R, Lucas J, Knight T, Zhao H, Menchine M. Opioid prescribing decreases after learning of a patient’s fatal overdose. Science. 2018;361:588–90. doi:10.1126/science.aat4595.
104. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34–47. doi:10.1016/j.drugalcdep.2014.10.001.
105. Franklin G, Sabel J, Jones CM, Mai J, Baumgartner C, Banta-Green CJ, Neven D, Tauben DJ. A comprehensive approach to address the prescription opioid epidemic in Washington State: milestones and lessons learned. Am J Public Health. 2015;105:463–69. doi:10.2105/AJPH.2014.302367.
106. Scherma M, Muntoni AL, Melis M, Fattore L, Fadda P, Fratta W, Pistis M. Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology (Berl). 2016;233:1765–77. doi:10.1007/s00213-015-4196-3.
107. Kohut SJ. Interactions between nicotine and drugs of abuse: a review of preclinical findings. Am J Drug Alcohol Ab. 2017;43:155–70. doi:10.1080/00952990.2016.1209513.
108. Agrawal A, Budney AJ, Lynskey MT. The co‐occurring use and misuse of cannabis and tobacco: a review. Addiction. 2012;107:1221–33. doi:10.1111/j.1360-0443.2012.03837.x.
109. Schauer GL, Berg CJ, Kegler MC, Donovan DM, Windle M. Assessing the overlap between tobacco and marijuana: trends in patterns of co-use of tobacco and marijuana in adults from 2003–2012. Addict Behav. 2015;49:26–32. doi:10.1016/j.addbeh.2015.05.012.
110. Schauer GL, Rosenberry ZR, Peters EN. Marijuana and tobacco co-administration in blunts, spliffs, and mulled cigarettes: a systematic literature review. Addict Behav. 2017;64:200–11. doi:10.1016/j.addbeh.2016.09.001.
111. Rabin RA, George TP. A review of co‐morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co‐use. Am J Addict. 2015;24:105–16. doi:10.1111/ajad.12186.
112. Dutra LM, Glantz SA, Arrazola RA, King BA. Impact of E-cigarette minimum legal sale age laws on current cigarette smoking. J Adolesc Health. 2018;62:532–38. doi:10.1016/j.jadohealth.2017.11.302.
113. US Department of Health Human Services. The health consequences of smoking–50 years of progress: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
114. Levy DT, Warner KE, Cummings KM, Hammond D, Kuo C, Fong GT, Thrasher JF, Goniewicz ML, Borland R. Examining the relationship of vaping to smoking initiation among US youth and young adults: a reality check. Tob Control. 2018;1–7. doi:10.1136/tobaccocontrol-2018-054446.
115. Miech RA, Schulenberg JE, Johnston LD, Bachman JG, O’Malley PM, Patrick ME.National adolescent drug trends in 2018 [press release]. Ann Arbor, MI: Monitoring the Future; 2018. Available at: http://www.monitoringthefuture.org
116. Huang J, Duan Z, Kwok J, Binns S, Vera LE, Kim Y, Szczypka G, Emery SL. Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market. Tob Control. 2019;28(2):146–51. doi:10.1136/tobaccocontrol-2018-054382.
117. Zhu S-H, Sun JY, Bonnevie E, Cummins SE, Gamst A, Yin L, Lee M. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23:iii3–iii9. doi:10.1136/tobaccocontrol-2014-051670.
118. Compton WM, Han B, Hughes A, Jones CM, Blanco C. Use of marijuana for medical purposes among adults in the United States. JAMA. 2017;317:209–11. doi:10.1001/jama.2016.18900.